Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jan 26, 2020 in Parkinson's Disease | 0 comments

In a nutshell

This study investigated the long-term effectiveness and safety of amantadine extended-release (Gocovri) in patients with Parkinson's disease (PD) and dyskinesia (DYS; unusual movements that a person cannot control). Researchers suggested that this treatment is associated with long-term improved outcomes.

Some background

PD is a chronic disease that affects brain cells. These cells lose their abilities causing symptoms such as tremors. The standard treatment is levodopa which is associated with long-term side effects such as DYS. Gocovri, is slowly released into the blood so its amounts in the body are more constant. This results in less variation of the drug in the blood, therefore preventing DYS.

Gocovri is already approved by the FDA, as the only drug to treat levodopa-induced DYS. However, too little is known about its long-term effectiveness and safety.

Methods & findings

This study included information about 223 patients with PD treated with Levodopa. The average diagnosis time was 11.7 years and levodopa usage was 9.3 years. Patients received Gocovri 274 mg once daily before bedtime. 57.8% of enrolled patients, completed the trial with an average treatment time of 1.9 years.

Common side effects to treatment were falls (32.7%), hallucination (seeing things that are not there; 24.2%), swelling of the limbs (16.1%), constipation (13.5%) and urinary infection (10.3%). 31 patients (13.9%) stopped treatment because of severe side effects.  

Gocovri showed greater improvement when compared to placebo (a drug with no effect on the body) for up to 2 years. A significant improvement was also seen in the patients who did not receive Gocovri before. This included patients who had undergone DBS (deep brain stimulation) and/or switched to Gocovri from regular amantadine. However, results were similar for all groups by week 8 and remained like that for the duration of the trial (100 weeks).

The bottom line

This study concluded that Gocovri is associated with long-term effectiveness and safety in patients with PD.

The fine print

This study was funded by Adamas Pharmaceuticals, the Gocovri manufacturer.

Published By :

Journal of Parkinson’s disease

Date :

Jan 06, 2020

Original Title :

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease.

click here to get personalized updates